Analysis DVA High Conviction Pick Cash Conversion result
NYQ Β· Healthcare Β· Medical Care Facilities
$190.31
+0.99 (+0.52%)
DVA Interactive Price Chart & Trading Signals
DVA Stock Snapshot β Valuation, Risk & Technical Signals
DVA Key Fundamentals, Analyst Targets & Company Profile
Key Financial Ratios
Market Cap
$12.14B
P/E Ratio
16.14
Forward P/E
11.03
PEG Ratio
0.46
P/B Ratio
-15.91
EPS
$11.79
Dividend Yield
β
52W Range
$101.00 β $247.49
Beta
0.83
Volume
0.1M
ROE
88.5%
Profit Margin
6.0%
Revenue Growth
5.2%
Gross Margin
32.4%
EV/EBITDA
9.43
Analyst Target
$219.86
The trailing price-to-earnings ratio stands at 16.1x. Forward P/E of 11.0x implies earnings expansion expected. EV/EBITDA sits at 9.43x. Market capitalization is $12.14B. Revenue is growing at 5.2% on a trailing basis. Earnings are expanding at 55.8%. Profit margins are 6.0%. Return on equity is 88.5%. Beta of 0.83 indicates market-average volatility.
Analyst Consensus
Recommendation
Buy
Low Target
$165.00
Mean Target
$219.86
High Target
$270.00
Based on 7 analysts
About DVA
DaVita Inc. provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis dialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers. In addition, the company offers integrated care and disease management services to patients in risk-based and other integrated care arrangements; clinical research programs; physician services; and comprehensive kidney care services. Further, it engages in the transplant software business. The company was formerly known as DaVita HealthCare Partners Inc. and changed its name to DaVita Inc. in September 2016. DaVita Inc. was incorporated in 1994 and is headquartered in Denver, Colorado.
DVA Deep Dive Analysis
Bottom Line
Verdict
UndervaluedBest for
Value-oriented investorsWatch out for
None flaggedData confidence
HighDaVita Inc. (DVA) trades below our multi-model fair value estimate of $366.67 by approximately 92.7%. Trailing P/E: 16.1x. Profitability signals include profit margin of 6.0% and return on equity of 88.5%. Recent growth metrics show revenue growth of 5.2% and earnings growth of 55.8%. Risk profile: beta of 0.83. Consensus: buy.
DVA Deep Dive Analysis
Valuation
Undervalued
P/E 16.1x
Price sits below our estimate of fair value.
Growth
Expanding
Rev 5.2%
Revenue is outpacing the market.
Valuation Snapshot
DaVita Inc. (DVA) trades below our multi-model fair value estimate of $366.67 by approximately 92.7%. The trailing price-to-earnings ratio stands at 16.1x. Forward P/E of 11.0x suggests earnings compression ahead. Price-to-sales is 0.9x. EV/EBITDA sits at 9.4x. Market capitalization is $12.14B.
Why it matters: Buying below fair value can create a margin of safety, but always check earnings quality.
Growth & Profitability
Revenue is growing at 5.2% on a trailing basis. Earnings are expanding at 55.8%. Profit margins are 6.0%. Return on equity is 88.5%. Return on assets is 7.5%.
Why it matters: Growing revenue with healthy margins usually means the business is gaining market share or pricing power.
Risk Profile
Beta of 0.83 indicates market-average volatility. Net debt position is $12.72B.
Why it matters: Lower risk means steadier returns, but often with less upside in bull markets.
Analyst Context
Analyst consensus target of $219.86 implies 15.5% upside. Target range spans $165.00 to $270.00. 7 analysts cover the stock. Consensus recommendation: buy.
Why it matters: Analyst targets reflect what professionals expect over 12 months. A wide gap between price and target can mean the market disagrees with the consensus.
Investor Fit
The combination of undervaluation and moderate risk may suit value-oriented investors. Free cash flow yield of 10.8% is attractive for cash-flow-focused investors.
Takeaway: Match the stock's risk-reward profile with your own goals and time horizon. No single metric tells the whole story.
Data Methodology & Sources
Market Data (Facts)
- Price, volume, market cap: Yahoo Finance (delayed ~5 min)
- P/E, EPS, revenue, debt: Yahoo Finance fundamentals
- Analyst targets: Yahoo Finance consensus (may lag)
- Insider trades: SEC EDGAR Form 4 filings
QuantSoar Model (Derived)
- Fair Value: 7-model consensus (DCF, Graham, P/E, P/S, DDM, EV/EBITDA, Div Yield) β trimmed inverse-variance weighted
- Margin of Safety = (Fair Value β Live Price) / Live Price Γ 100
- Composite Score: 40% Value + 30% Momentum + 30% Risk
- Verdict Gauge: Base 50 + Valuation(Β±25) + Whale(Β±10) + Macro(Β±10) + Technical(Β±10). Analyst consensus shown separately.
Model outputs are estimates based on available data and are not investment advice. Cross-check with primary sources before making investment decisions.
DVA Undervalued
DaVita Inc. (DVA) trades below our multi-model fair value estimate of $366.67 by approximately 92.7%.
Frequently Asked Questions
ValuationIs DVA stock overvalued right now?
ValuationWhat is DVA fair value based on current fundamentals?
RiskHow risky is DVA compared with other stocks?
GrowthIs DVA still growing?
AnalystWhat do analysts think about DVA?
CatalystWhat could change the investment case for DVA?
Related Stocks
About the Author
Phasakorn Traklang (Peach) β Founder
Phasakorn Traklang (Peach) is the founder of QuantSoar, bringing expertise in SEO, web development, and technical analytics to build an AI-powered investment platform accessible to retail investors worldwide.
Connect on LinkedInInvestment Disclaimer: QuantSoar is for informational purposes only. We do not provide personalized investment advice. Always conduct your own research or consult a financial advisor. SEC
Data: Yahoo Finance / SEC EDGAR / Alpha Vantage / Finnhub. AI outputs verified against source data.